Biogen Inc.

NasdaqGS:BIIB

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Pharmaceuticals

Location

United States

Market Cap

USD 18.61 B

Share Price

USD 127.04

Avg Daily Volume

1,772,992

Change (1 day)

0.40%

Change (1 year)

-43.68%

Change (YTD)

-16.92%

Biogen Inc. Total Liabilities for the year ending December 31, 2024: USD 11.33 B

Biogen Inc. Total Liabilities is USD 11.33 B for the year ending December 31, 2024, a -5.91% change year over year. Total liabilities are the total amount of a company's debts and other obligations.

Biogen Inc. Total Liabilities for the year ending December 31, 2023 was USD 12.05 B, a 7.88% change year over year.
Biogen Inc. Total Liabilities for the year ending December 31, 2022 was USD 11.17 B, a -13.56% change year over year.
Biogen Inc. Total Liabilities for the year ending December 31, 2021 was USD 12.92 B, a -7.29% change year over year.
Biogen Inc. Total Liabilities for the year ending December 31, 2020 was USD 13.93 B, a 0.27% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Total Liabilities	Shareholders' Equity	Cash and Short-Term Investments	Receivables

NasdaqGS: BIIB

Biogen Inc.

CEO	Mr. Christopher A. Viehbacher
IPO Date	Sept. 17, 1991
Location	United States
Headquarters	225 Binney Street
Employees	7,605
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Pharmaceuticals

Description

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.